Drugs / omega-3 fatty acid ethyl esters
omega-3 fatty acid ethyl esters
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03831698 | Feb 2019 → Jun 2022 | Lynch syndrome | University of Kansas Medical Center | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01813110 | May 2014 → Apr 2015 | — | Penn State University | Completed | No outcome recorded |
| — | NCT01577056 | Apr 2012 → Dec 2013 | familial hypercholesterolemia, hypertriglyceridemia | The University of Western Australia | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega-3 fatty acid ethyl esters | “Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia.” PMID 37202042 ↗ Mar 20232“pharmacological dose of omega-3 fatty acid ethyl esters (P-OM3, 3.4 g/d EPA + DHA)” NCT01813110 ↗ |
| Known as | n-3 fatty acid ethyl esters | “This study will examine the effect of oral n-3 fatty acid ethyl esters supplementation (4g/day, Omacor) on postprandial hypertriglyceridaemia and post-prandial arterial...” NCT01577056 ↗ |
| Known as | Omacor | “This study will examine the effect of oral n-3 fatty acid ethyl esters supplementation (4g/day, Omacor) on postprandial hypertriglyceridaemia and post-prandial arterial...” NCT01577056 ↗ |
| Known as | P-OM3 | “pharmacological dose of omega-3 fatty acid ethyl esters (P-OM3, 3.4 g/d EPA + DHA)” NCT01813110 ↗ |
| Known as | ω-3FAEEs | “Treatment with omega-3 fatty acid ethyl esters (ω-3FAEEs) in FH patients has been shown to improve postprandial triglyceride-rich lipoprotein (TRL) metabolism, including...” PMID 37202042 ↗ Mar 2023 |
| Route | Oral | “oral supplementation with 4 g/d ω-3 FAEE” PMID 27490922 ↗ Aug 2016 |